Evofem Biosciences, Inc. Common Stock
EVFM
EVFM was delisted on the 10th of August, 2022.
19 hedge funds and large institutions have $80.7M invested in Evofem Biosciences, Inc. Common Stock in 2019 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 5 increasing their positions, 5 reducing their positions, and 1 closing their positions.
300% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 1
19% more funds holding
Funds holding: 16 → 19 (+3)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 5
6% less capital invested
Capital invested by funds: $86.2M → $80.7M (-$5.46M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WIM
Woodford Investment Management
London,
United Kingdom
|
+$7.04M |
| 2 |
Invesco
Atlanta,
Georgia
|
+$1.54M |
| 3 |
HA
Heartland Advisors
Milwaukee,
Wisconsin
|
+$187K |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$124K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$106K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
-$27.8K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$18.2K |
| 3 |
Millennium Management
New York
|
-$16.8K |
| 4 |
TWMP
Taylor Wealth Management Partners
Boston,
Massachusetts
|
-$7.58K |
| 5 |
BlackRock
New York
|
-$3.19K |
EVFM Hedge Fund Activity: Q1 2019 in Review
19 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Evofem Biosciences, Inc. Common Stock (EVFM) for Q1 2019, worth a combined $80.7M — down 6.3% from $86.2M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new EVFM positions and 1 closed out — a net gain of 3 holders — while 5 added to existing stakes and 5 trimmed.
The largest buyer was Woodford Investment Management, adding an estimated $7.04M. The largest seller was Panagora Asset Management, cutting an estimated $27.8K.
- 19 institutional investors held Evofem Biosciences, Inc. Common Stock (EVFM) as of Q1 2019, up from 16 in Q4 2018.
- Funds reported $80.7M of Evofem Biosciences, Inc. Common Stock stock for Q1 2019, down 6.3% quarter-over-quarter.
- 4 funds opened new Evofem Biosciences, Inc. Common Stock positions in Q1 2019 and 1 closed out, a net change of +3 holders.
- The largest Evofem Biosciences, Inc. Common Stock buyer in Q1 2019 was Woodford Investment Management, an estimated $7.04M added.
- The largest Evofem Biosciences, Inc. Common Stock seller in Q1 2019 was Panagora Asset Management, an estimated $27.8K sold.
Based on aggregated 13F filings for Q1 2019.